TPEx: 6589

EirGenix, Inc.

A New Asia Development & Manufacturing Hub for Biologics

Company Introduction

2021/09/02 ICA Conference

Forward Looking Statement Disclaimer

All information and other statements contained in this presentation, other than statements of historical fact, constitute forward looking statements within the meaning of federal securities laws. These forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could affect our future results and cause actual results and events to differ materially from our historical and expected results and those expressed or implied in these forward-looking statements.

March 15, 2013

Signed agreement with DCB

~9%

Formosa Laboratories, Inc.

Employee Education Level:



Total Employees: 270

Top 10 Investors

(as of 2021/04/24)

Shareholder	% Shares
Formosa Laboratories, Inc.	8.25%
National Development Fund	6.52%
Yaohua Glass CO., Ltd. Management Committee	5.58%
Taiwania Capital	4.67%
Wreker Pan	4.65%
Development Center for Biotechnology	2.61%
CTBC Venture Capital	2.16%
CTBC Capital - MOEA Small and Medium Enterprise Administration Assets	1.19%
中國信託商業銀行受託保管台康生技（股）公司	0.93%
先進國際投資股份有限公司	0.91%
TOTAL	**37.47%**

Note: Total of Employee Shareholders = 4.46% (2021/04/24)

A Strong and Experienced Senior Management Team:

> 200 years
Experience in the industry

Lee-Cheng (L-C) Liu, Eng.Sci.D. | **President & CEO**

Ex-President & COO of **AnGes** with **30 years** of leadership experience in Pharma, Biotech and specialty chemical industries. He holds a doctoral degre **Columbia University**.

Thomas Schulze, Ph.D. | **Managing Director, EirGenix Europe GmbH**

Ex-CEO of **Formycon** and **Avontec** with more than **25 years** of leadership experience in Pharma (Bayer AG) and Biotech. He holds a Ph.D. from **Free University Berlin** (**Max-Planck Institute**).

Chih-Jung (CJ) Chang, Ph.D. | **VP, COO**

Ex-Director of PM for Oncology at **TTY** with **20 years** experience in pharmaceutical industry. He holds a PhD from **National Taiwan University**.

Ping-Yang Ye, Ph.D. | **VP, CTO**

Ex-Executive director of Amgen, with more than **23 years** of experience of process and product development experience in Biogen-IDEC, GSK及SmithKline Beechman. He holds a doctoral degree from **University of Utah (Salt Lake City)**.

Cathy (Hsiu-Chuan) Yang | **VP, CFO**

Ex-General Manager of **ERS, a JV company between Fresenius and Excelsior**, overseeing the operations of 100+ kidney dialysis centers in Taiwan. She holds a Master of Science in Accounting from **University of New Haven** and has **20 years** of experiences in FMCG and medical industries.

James (Chih-Dung) Teng | **VP, Quality System**

Ex-QA executive in Mycenax and Holly Stone Healthcare, Co., with more than 25 years of experience in GMP, quality assurance, quality control and manufacturing in pharmaceutical industry

Sheng-Chung Ju, Ph.D. | **Executive Director, Engineering & Manufacturing**

Ex-Head of Production at **DCB BPPF** with 25 years experience of development and production of biologics. He holds a Ph.D. from **NTU.**

Irene (Ai-Ning) Lin | **Executive Director, AS/QC**

Ex-head of Purification and Protein Characterizations at **DCB BPPF** with **25 years** of experience of biologic product R&D. She holds a Ph.D. from **University of Maryland** College Park.

Barbara Gromann-Izay MD | **Senior Director, Medical Affairs & Clinical Operations, EirGenix Europe GmbH**

Ex-AOP Clinical Development Director, with **17 years** of experience in Baxter, Wyeth, Hoopkin Bio served as a Clinical Operation management position. She holds a MD degree from **University of Vienna**

Dual Business Model



EirGenix's Profile & Current Developments

- Dual Business Model: CDMO Services and Internal Product Development
- Since the establishment of EirGenix, a total of NTD 8.248 billion in cash has been raised and a joint loan signed with Taiwan Enterprise Bank valued at NTD 850 million for facility construction. The joint loan has since increased to NTD 1.05 billion as of May 6, 2020. An additional NTD 300 million of convertible corporate bonds has been subscribed and guaranteed by Taichung Bank
- Broad and diversified product pipeline (total 6); a unique strategy of HER2 products franchise management
- Rapidly growing Contract Development & Manufacturing (CDMO) service business – break even achieved in 2016
- Newly constructed Zhubei commercial production plant was on-line on January 23, 2019
- On April 29, 2019, signed a global licensing agreement (excluding Taiwan and Mainland China) with Sandoz AG for EG12014 that includes upfront and milestone payments, plus profit sharing of the future sales
- Successfully completed IPO in TPEx on June 28, 2019.
- EirGenix received PMDA's official approval on February 3rd, 2020 and was issued PMDA's "GMP compliance Inspection Result Notification", proclaiming EirGenix's compliance with relevant Japanese regulations regarding the quality, effectiveness and safety of pharmaceutical manufacturing. On March 3, 2021, EirGenix signed a long-term supply agreement with a Japanese pharmaceutical company, marking the first for a Taiwanese company to provide long-term supply of a marketed biological drug on the Japanese market. The product is a staple for cancer treatment with the Japanese market representing 30% of total market share.

EirGenix's Recent & Current Developments

- The multi-country, multi-center Phase III clinical trials for **biosimilar drug EG12014** was conducted in 91 clinical centers in 11 countries around the world where 807 patients were admitted by March 25, 2020. The pre-operative neoadjuvant therapy and tumor removal surgery for the last patient in was completed at the beginning of November 2020. **On March 23, 2021, the analysis of the Phase III clinical trials concluded that EG12014 had met its primary endpoint**, showing equivalent efficacy to the originator drug and demonstrated a comparable safety profile. Submissions of Biological License Application (BLA) to U.S. FDA and Market Approval Application to EMA are now being prepared.
- In December 2019, EirGenix's German subsidiary, EirGenix Europe GmbH was established, with its main task to manage and execute clinical development of EirGenix's biological products.
- Awards Record:
  - ✓ 2018/01/31 Asia's Best Biologics CMO Award
  - ✓ 2018/11/30 Winner of 15th Annual National Innovation Award (Biotech/Pharmaceutical)
  - ✓ 2018/12/31 Deloitte 2018 Technology Fast 500 Asia Pacific , Ranking No. 324
  - ✓ 2019/02/27 BioProcessing Excellence in Taiwan Award
  - ✓ 2019/04/10 Winner of 6th MOEA National Innovation Award (Small and Medium-Sized Enterprise)
  - ✓ 2019/07/26 Winner of 2019 Taipei Biotechnology Award (New Innovation Technology Excellence Award)
  - ✓ 2019/12/06 Winner of National Innovation Award (Enterprise Innovation Award)
  - ✓ 2020/07/08 BioProcessing Excellence in Greater China Area Award

EirGenix's Product Pipeline

Development	IND / Phase I/II	Phase III	MAA/BLA Submission	BD/Alliance
EG12014 (Trastuzumab) Biosimilar l Breast Cancer	4Q 2015 EU	4Q 2018 Global	2021 US BLA	PARTNERED WITH SANDOZ Signed global licensing agreement with Sandoz AG (Novartis) on 2019/4/29 for all markets except mainland China and Taiwan. The agreement includes milestone payments and profit sharing of sales in authorized markets.
EG1206A (Pertuzumab) Biosimilar l Breast Cancer				(Currently confidential)
EG13074 (Trastuzumab – SC Formulation) Biobetter l Breast Cancer				(Currently confidential)
TSY0110 (EG12043 – ado-trastuzumab) Biosimilar l Breast Cancer				Joint development with Formosa Laboratories, with its subsidiary Formosa Pharmaceuticals responsible for clinical development
EG12021 Biosimilar l Cancer				After completing 3-4 consistent batch runs and demonstrating similarity, product will be available for global market authorization. Right reserved to treat macular eye disease.
EG74032 Carrier Protein l Vaccines for infectious diseases and cancer		*No need of clinical development, only file DMF		Joint development with new drug development in Taiwan. Material has been provided to new vaccine R&D companies in Europe, Japan, Canada, and the United States (NIH)
EG62054 Biosimilar l AMD & Cancer				

HER2 Family Products

EirGenix's CDMO Services

Full-Service CDMO Services

One-Stop Solution from DNA to NDA/BLA



Business Performance



- CDMO Revenue
- Sales Revenue
- Total Revenue
- CDMO Signed Contract Value

Fundraising Capital Utilization (2012/12 – 2021/06)



Product Development:
NTD 3.716 B

A. CDMO Profit:
Historical gross profit plus depreciation and amortization

B. Running Cash:
Admin. operation and market development expenses, inventory and advance payment

**Fundraising is mainly used for product development and equipment purchase; the gross profit generated by CDMO is in addition to supporting the company*

Factors Affecting Market Value of Biosimilar Companies

	Celltrion	Momenta ★	Coherus	Tanvex	Formycon	EirGenix	Pfenex ※	Samsung Biologics
Ongoing/Completed Phase III Clinical Results (under review)	√ (4+1)	√ (0+1)	√ (1+2)	√ (0+1)	√ (0+1)		√ (1)	√ (5+1)
Joint Development or Regional Authorized Partners	√	√	√		√	√		√
Products Under Phase III Clinical Development	√	√	√	√	√	√	√	√
Internal Manufacturing Capacity	√			√		√		√
Matched Items	**4**	**3**	**3**	**3**	**3**	**3**	**2**	**4**
Total Market Capital (US$ Million)	**33,031**	**NA**	**1,147**	**527**	**635**	**1,147**	**NA**	**56,954**

*Based on market data on 2021/08/23

★ Momenta was acquired by Johnson & Johnson.

※ Pfenex was acquired by Ligand.

EirGenix's Past Performance & Future Vision

Acquired DCB BPPF

Started Construction of Zhubei Facility

Initiated Zhubei facility operation

EG12014 P3 Clinical Start

Signed EG12014 Licensing Agreement with Sandoz

EG12014 BLA The first biosimilar launch

EG13074

EG1206A

EG62054

CDMO Income + API margin
Biosimilar sales profit share

Licensing Milestone Payments

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030

CDMO Business P&L Break-Even

EirGenix's COVID-19 Anti-Epidemic Activities

Cooperative Units: Domestic and foreign academic and research circles and hospitals, etc.
Cooperators: Domestic and foreign antibody development and vaccine companies, etc.

EirGenix

EirGenix, Inc.

AEP Alliance – Vstrip® COVID-19 Antigen Rapid Test

PRODUCT HIGHLIGHTS

1. **Rapid test results within 10 minutes.**

2. **Functional for early-stage infections.**

3. **Utilizes nasal mucus from the nasopharyngeal cavity.**

4. **No equipment required.**

- **2020/08/27** Vstrip® Antigen Rapid Test obtains TFDA Emergency Use Authorization (EUA), the first in Taiwan for antigen rapid tests; 2021/05/03: Cassette version receives EUA.
- **2020/09/25** Received approved validation from Indian Council of Medical Research (ICMR) and sales license; 2021/03/09: Received official import license in India
- **2020/12/02** Obtained EU's CE-IVD Authorization (Reference Number: BS0266-2020)
- **2020/12/24** Obtained Temporary Authorization from Singapore's Health Sciences Authority
- **2021/02/02** Acquired Belgian Free Sales Certificate (Free Sales Certificate No.: 000003 26-01-21)

EirGenix & Medigen Vaccine Biologics (MVC)

Provide full services from early process development to large scale production for MVC's COVID-19 vaccine MVC-COV1901

COVID-19 S-2P Protein

Antigen



Well-established adjuvant



This is a warp speed development project to assist the client (MVC) developing a vaccine candidate from cell line development to be ready for clinical trial within 6 months. With a satisfactory phase 1 result, MVC got the approval from TFDA to start the large phase 2 (total more than 3,700 subjects) clinical trial. Upon completion of Phase 2 trial with satisfactory results, the NHCC may grant an EUA as part of the vaccination program. EirGenix has already produced enough drug substance of S2P antigen for MVC to prepare for more than 4 million doses of MVC-COV1901

感謝狀

茲感謝 台康生技股份有限公司
熱心參與國家衛生研究院感染症與疫苗研究所執行之[開發新型冠狀病毒疫苗]計畫，並無償提供自有產品強化疫苗能力的載體蛋白(CRM197)供應疫苗開發。

謹致此狀 敬表謝忱

院長 梁賡義

中華民國一零九年五月四日

Appreciation letter from NHRI-Taiwan for providing them free carrier protein (CRM197) for their vaccine development programs.

Taiwan & EirGenix can Help!

Clients' Success Is Our Priority

EirGenix, Inc.
台康生技股份有限公司

6589